Wellness
GLP-1s, peptides, and pregnancy: what you actually need to know
These medications are reshaping how women manage their metabolic health. If you’re in your childbearing years and considering either, here’s what the evidence actually says — and the questions worth asking before you start.
10 min read
These medications have moved quickly from endocrinologist offices into mainstream wellness. GLP-1 receptor agonists are now prescribed by primary care physicians, offered at weight loss clinics, and discussed openly in wellness communities. Therapeutic peptides like BPC-157 occupy a murkier space — widely available, loosely regulated, and circulating in the same conversations. Both are now being used by women who are also thinking about pregnancy.
This isn’t a verdict on either. It’s an honest account of what is known, what isn’t, and what the specific considerations are for women in their childbearing years. The goal is to give you better questions to bring to your provider — not to answer them for you.
01
GLP-1 medications: what they are and why women are taking them
GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda) — mimic a gut hormone that slows gastric emptying, reduces appetite, and stimulates insulin release. The result, for most people, is sustained and significant weight loss. They were developed for type 2 diabetes and obesity; their reach has expanded considerably.
The relevance to reproductive health goes beyond weight. Metabolic and reproductive function are deeply connected, and PCOS — affecting up to 10% of reproductive-age women and the most common cause of ovulatory infertility — is rooted in insulin resistance. GLP-1s address that root cause directly. For some women, they restore ovulatory cycles that had been absent for years.
The “Ozempic baby” phenomenon
There are growing reports of unexpected conceptions after starting GLP-1 therapy. The mechanism is plausible: improved insulin sensitivity restores ovulatory cycles. Any woman on a GLP-1 who is not trying to conceive should discuss contraception explicitly with her provider — and note that tirzepatide specifically may affect oral contraceptive absorption.
02
What the evidence says about GLP-1s and pregnancy
Do they cause birth defects? Animal studies at high doses raised developmental concerns. A 2025 systematic review examining over 1,100 semaglutide-exposed pregnancies found no consistent link to major congenital malformations — but the data set is small and observational. It is not large enough to be definitively reassuring, and it was not designed to be.
Is it safe to use during pregnancy? No GLP-1 is currently approved for use during pregnancy. Both the FDA and MHRA guidance is to discontinue before conception. This is a precautionary position based on insufficient data — not a position based on confirmed harm. That distinction matters, but it doesn’t change the practical recommendation.
How far in advance should you stop? Semaglutide has a seven-day half-life — complete clearance takes approximately two months. Tirzepatide is similar. Liraglutide clears faster, in a matter of weeks. The working recommendation is at least two months before trying to conceive; discuss the specifics with your prescriber.
Can GLP-1s help with fertility before pregnancy? For women with PCOS or obesity-related ovulatory dysfunction, the evidence suggests yes — by addressing the underlying insulin resistance that drives the problem. This is an active area of research, not a fringe claim.
The absence of confirmed harm is not the same as confirmed safety. In pregnancy, that distinction is worth holding carefully.
03
Therapeutic peptides: a very different conversation
BPC-157 and TB-500 are synthetic peptides marketed for tissue repair, recovery, gut healing, and inflammation. They are not GLP-1s — they operate through entirely different mechanisms and exist in a different regulatory environment. Understanding them as “similar to Ozempic” is a mistake.
Almost all research on BPC-157 and TB-500 is preclinical — rodent models, in vitro work. Human trials are extremely limited. In late 2023, the FDA added BPC-157 to its list of substances presenting significant safety risks, citing concerns about immune reactions, peptide impurities in commercial preparations, and the absence of adequate human safety data.
For women in their childbearing years: there is no human reproductive safety data for BPC-157 or TB-500. Not limited data. No data. The “99% purity” claims from commercial suppliers are not independently verified and should not be treated as a safety assurance.
The absence of data is different from the absence of risk. In the context of fertility and early pregnancy, it is a meaningful reason to pause.
04
The questions worth asking yourself
Where you are in your reproductive timeline changes the calculus significantly.
Not yet trying to conceive
GLP-1s may offer genuine metabolic benefit — particularly for women with PCOS or insulin resistance. The key is building a clear discontinuation timeline with your provider well before you intend to try. Peptides without human reproductive safety data are a different risk profile entirely.
Actively trying to conceive
GLP-1s should already be discontinued, with adequate clearance time accounted for. No therapeutic peptide without established reproductive safety data should be in active use during this window.
Currently pregnant
Neither GLP-1s nor therapeutic peptides like BPC-157 are recommended during pregnancy. The absence of data supporting their safety during gestation is itself the reason.
Postpartum or breastfeeding
Current guidance leans toward avoiding GLP-1s until after weaning, though this is an evolving area. Peptides remain an open question — and an open question is not a green light.
05
Where things actually stand
GLP-1s before conception
May benefit women with PCOS or insulin resistance. Plan discontinuation at least 2 months before trying.
GLP-1s during pregnancy
Not recommended. Precautionary guidance — based on insufficient data, not confirmed harm.
GLP-1s and contraception
Verify your contraception is reliable, particularly with tirzepatide — potential interaction with oral contraceptives.
Therapeutic peptides (BPC-157, TB-500)
No human reproductive safety data exists. Meaningful reason to pause for women considering pregnancy.
Commercial peptide purity claims
Treat “99% pure” claims from commercial suppliers with scepticism — not independently verified.
This article is for informational purposes only and does not constitute medical advice. It reflects publicly available research as of mid-2026. Always consult a qualified healthcare provider before starting, stopping, or adjusting any medication or therapeutic compound, particularly in the context of fertility or pregnancy.